Orally Disintegrating Tablets: The Effect of Recent FDA Guidance on ODT Technologies and Applications - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Orally Disintegrating Tablets: The Effect of Recent FDA Guidance on ODT Technologies and Applications
The authors describe the various available technologies used in orally disintegrating tablets.


Pharmaceutical Technology


References

1. FDA, CDER data standards manual (C-DRG-00201 Version 008), http://www.fda.gov/Drugs/DevelopmentApprovalProcess/FormsSubmissionRequirements/ElectronicSubmissions/DataStandardsManualmonographs/ucm071666.htm/, accessed Aug. 20, 2009.

2. FDA, Guidance for Industry: Orally Disintegrating Tablets (Rockville, MD, Dec. 2008), http://www.fda.gov/OHRMS/DOCKETS/98fr/FDA-2007-D-0365-gdl.pdf, accessed Aug. 20, 2009.

3. European Pharmacopeia, Version 6.5, 2009.

4. EMEA, Committee for Medicinal Products for Human Use (CHMP), Reflection Paper: Formulations of Choice for the Paediatric Population, Adoption by CHMP Sept. 21, 2006, http://www.emea.europa.eu/pdfs/human/paediatrics/19481005en.pdf, accessed Aug. 20, 2009.

5. S. Freedman et al., "Oral Ondansetron for Gastroenteritis in a Pedatric Emergency Department," New Eng. J. of Med. 354 (16), 1698-1705 (2006).

6. R. Bohnacker et al., "Bestimmung der Zerfallszeit von Schmelztabletten mit Hilfe der Texture Analyser-Methode," Pharm. Ind. 67 (3), 327–335, (2005).

7. D. Gole et al., "Pharmaceutical and Other Dosage Forms," US patent 5,648,093, 1997.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Source: Pharmaceutical Technology,
Click here